Middle East IVD market to recover to pre-pandemic growth rates from 2024

Article tags Centralised Diagnostics (CEDx)Molecular Diagnostics (MDx)Point-of-care testing (POCT)Middle East & AfricaCentralised Diagnostics (CEDx)IVD GatewayMolecular Diagnostics (MDx)Point-of-care testing (POCT)

The Middle East IVD market has mostly recovered to pre-pandemic levels. Without accounting for revenue for SARS-CoV-2 tests, the Middle East IVD market is expected to grow at an annual average of 8% from 2021 to 2026. 

The period of 2023 to 2024 is expected to be a critical period of post-pandemic recovery for IVD markets in the region. The Middle East is projected to decline in 2023 after a slowdown since the covid-19 pandemic in 2020. After the growth rate bottoms out in 2023, the market is expected to climb back towards its organic growth trajectory from 2024 onwards. 

As the pandemic winds down, centralised diagnostics (CEDx) will be the main driver of growth in the region. CEDx is the biggest market segment in the Middle East, making up around half of the region’s total IVD market.

Essential 2021-2026 insights on the Middle East IVD market:

• Middle East’s CEDx market is set to grow faster than other emerging regions including Asia-Pacific and Latin America. 
• Strong CEDx growth in the next few years is expected in the larger Middle East economies such as Saudi Arabia and the United Arab Emirates, where the segment is expanding faster than the overall regional growth rate.
• Molecular diagnostics (MDx) is expected to contract more than 10% annually in the same period. 
• Point-of-care testing (POCT) is growing at a slower rate of around 3%.

Wed, 23rd Nov 2022 Article tags Centralised Diagnostics (CEDx)Molecular Diagnostics (MDx)Point-of-care testing (POCT)Middle East & AfricaCentralised Diagnostics (CEDx)IVD GatewayMolecular Diagnostics (MDx)Point-of-care testing (POCT)